Loading
Led the selumetinib trials that gave children with neurofibromatosis their first approved drug.
Brigitte C. Widemann is Chief of the Pediatric Oncology Branch and Special Advisor to the NCI Director for Childhood Cancer at the National Cancer Institute. She is a paediatric oncologist known for the neurofibromatosis type 1 plexiform neurofibroma studies that led to selumetinib's approval, the first approved drug for children with the condition. Her selected paper reports selumetinib in children with inoperable plexiform neurofibromas. She now leads NCI's paediatric oncology branch and its rare tumour initiatives, with interests spanning neuroblastoma and sarcomas.
| Title | Journal | Year |
|---|---|---|
| Selumetinib in children with inoperable plexiform neurofibromas | New England Journal of Medicine | 2020 |
Shares Neuroblastoma (paediatric), National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares Neuroblastoma (paediatric), National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).